AZ Jan Palfijn Gent
13
2
3
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
7.7%
1 terminated/withdrawn out of 13 trials
85.7%
-0.8% vs industry average
46%
6 trials in Phase 3/4
33%
2 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Diagnosing Drug Allergy: the T is the Key
Role: collaborator
Diversity in Patients With OAB
Role: collaborator
The Belgian SMART Study Evaluating the Use of Golimumab for Ulcerative Colitis
Role: collaborator
Metabotyping of Overweight and Obese Children
Role: collaborator
Move ARound And Get Active: an Intervention to Optimize 24-hour Movement Behaviours in Preschoolers
Role: collaborator
Effects of Detraining in Endurance Athletes With Atrial Fibrillation
Role: collaborator
Myo-inositol Versus Clomiphene Citrate in PCOS
Role: collaborator
Elonva in Combination With Hp-FSH Versus Elonva With Low Dose hCG
Role: lead
Trial Comparing hCG Triggering Versus GnRH Agonist Triggering in PCOS Patients
Role: lead
Oxytocin Antagonist in Patients With Repeated Failure of Implantation
Role: lead
Effect of Recombinant Follicular Stimulating Hormone (FSH) Dosing Following Cori-follitropin Alfa
Role: collaborator
The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.
Role: lead
Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist
Role: lead
All 13 trials loaded